Prothena | PRTA - Des Atouts





Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
Akebia Therapeutics USD 362.52M 14.04M 2026-03
ALKERMES USD 4.26B 1.77B 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Amgen USD 92.5B 1.92B 2026-03
Biogen USD 29.48B 43.6M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Exelixis USD 2.59B 250.83M 2026-03
Immunic USD 24.05M 16.65M 2025-12
Incyte USD 7.34B 381.14M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
MacroGenics USD 256.85M 13.92M 2025-12
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Prothena USD 349.89M 23.09M 2026-03
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Ultragenyx Pharmaceutical USD 1.3B 236M 2026-03
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03
Xoma USD 263.15M 39.7M 2025-09